Despite a decrease in net asset value and net profit, Flerie AB remains optimistic about future growth through innovative investments and a robust cash position.
Flerie increased its shareholding in Xspray Pharma and commented on FDA feedback on Dasynoc. Shareholders, financial analysts and media are kindly invited to a webcast in English, including ...
10d
Flerie AB (STU:1NP1) reports a robust increase in net asset value and successful NASDAQ Stockholm listing, despite challenges in the biotech sector.
Ted Fjällman, PDG de Flerie, achète des actions pour près de 0,3 million de SEK 07/08 FW La valeur de l'actif net de Flerie a ...
Le 17 octobre, Roseberry a acheté 5 639 actions de la société d'investissement Flerie. Les actions ont été achetées au prix ...
Wellcome Sanger Institute spin-out Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Being Tested in Combination with MSD's anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab)CAMBRIDGE, United Kingdom, Oct. 07, 2024 (GLOBE NEWSWIRE ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback